Anlon Healthcare Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Anlon Healthcare Ltd filed with BSE on 09 Jun 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Anlon Healthcare reported FY26 consolidated total income of INR 172.22 crore, up 42.98% year-on-year, with EBITDA up 47.55% and PAT up 41.77%. Q4 FY26 total income was INR 50.90 crore versus INR 48.97 crore a year earlier, while reported PAT of INR 11.07 crore was lower than INR 16.65 crore in the year-ago quarter due to higher operating and development expenses. Management discussed the completed acquisitions of Apiqo Organics and Bizotic Life Science, capacity expansion plans, and provided revenue and margin outlook for FY27 and FY28.
Numbers mentioned
Total income: INR 172.22 crore (FY26)
p. 2
“total income for FY26 grew 42.98% year-on-year to INR 172.22 crore from INR 120.46 crore in FY25”
Punit Rasadia, page 2 of the filed PDF · View the filing
EBITDA growth: 47.55% (FY26)
p. 2
“EBITDA increased 47.55% to INR 47.77 crore while profit after tax grew 41.77% to INR 29.09 crore”
Punit Rasadia, page 2 of the filed PDF · View the filing
Q4 total income: INR 50.90 crore (Q4 FY26)
p. 2
“For the fourth quarter, total income stood at INR 50.90 crore compared to INR 48.97 crore in Q4 FY25”
Punit Rasadia, page 2 of the filed PDF · View the filing
Q4 PAT: INR 11.07 crore (Q4 FY26)
p. 2
“Reported PAT of INR 11.07 crore was lower than the INR 16.65 crore in the corresponding quarter, primarily on account of higher operating and development expense as we scale the platform”
Punit Rasadia, page 2 of the filed PDF · View the filing
Capacity utilization: approx 62% (FY26)
p. 2
“our facilities operating at a healthy capacity utilization of approx 62% at consolidated basis”
Punit Rasadia, page 2 of the filed PDF · View the filing
Combined installed capacity: 1400 to 1600 metric ton per annum
p. 3
“our combined installed capacity has expanded to approximately 1400 to 1600 metric ton per annum”
Punit Rasadia, page 3 of the filed PDF · View the filing
Order book: INR 280 to 300 crore (FY27)
p. 6
“right now we have the clear visibility in terms of the order book is somewhere around INR 280 to 300 CR for the whole year in consolidation basis”
Punit Rasadia, page 6 of the filed PDF · View the filing
Receivable days: 130 to 140 days
p. 7
“right now the receivable days is somewhere between after invoice making, you have to consider 130 to 140 days”
Punit Rasadia, page 7 of the filed PDF · View the filing
Recovered receivable from distributor: INR 11 crore
p. 16
“we have already recovered the almost INR 11 CR from there and I think within next one quarter we'll able to get the mostly total whatever the receivable from them”
Punit Rasadia, page 16 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue — INR 380 to 400 crore · FY27
stated firmly by Punit Rasadia
p. 3
“That should be right now the whatever the visibility we are having, it is between INR 380 to 400 CR for FY27”
Punit Rasadia, page 3 of the filed PDF · View the filing
Revenue — 700 to 800 crore · FY28
stated conditionally by Punit Rasadia
p. 4
“Yeah, FY28 we are expecting between 700 to 800 CR”
Punit Rasadia, page 4 of the filed PDF · View the filing
Revenue CAGR — approximately 30% · next three years
stated as an aspiration by Punit Rasadia
p. 3
“we remain confident of delivering approximately 30% of revenue CAGR over the next three years while working towards maintaining EBITDA margin in the range of 25 to 30%”
Punit Rasadia, page 3 of the filed PDF · View the filing
EBITDA margin — 25 to 30% · FY27
stated conditionally by Punit Rasadia
p. 5
“If things will be normal as per the pre-war situation, then we'll able to maintain the same EBITDA margin, otherwise it may impact on the EBITDA margin”
Punit Rasadia, page 5 of the filed PDF · View the filing
Peak revenue potential — INR 450 to 500 crore
stated as an aspiration by Punit Rasadia
p. 3
“I think we may go up to the INR 450 to INR 500 CR in the peak capacity of the consolidation”
Punit Rasadia, page 3 of the filed PDF · View the filing
New Capex — INR 130 crore
stated firmly by Punit Rasadia
p. 4
“the Capex is expected somewhere around INR130 CR”
Punit Rasadia, page 4 of the filed PDF · View the filing
New facility commissioning — Q1 FY28
stated firmly by Punit Rasadia
p. 4
“Uh, mostly by Q1 of FY28”
Punit Rasadia, page 4 of the filed PDF · View the filing
New facility peak revenue (standalone Anlon) — INR 400 to 450 crore
stated as an aspiration by Punit Rasadia
p. 4
“if we'll consider the standalone Anlon with the expansion, then we can go up to the INR 400 to INR 450 CR in the standalone at the peak level”
Punit Rasadia, page 4 of the filed PDF · View the filing
New capacity utilization — 50 to 60% · FY28
stated as an aspiration by Punit Rasadia
p. 4
“Yeah, that we are considering at least we'll use the 50 to 60% in FY28”
Punit Rasadia, page 4 of the filed PDF · View the filing
Cash flow from operations — positive · FY27
stated firmly by Punit Rasadia
p. 7
“Mostly FY end of FY27, it will be positive”
Punit Rasadia, page 7 of the filed PDF · View the filing
Term loan for expansion — INR 65 to 70 crore
stated firmly by Punit Rasadia
p. 7
“we are planning to get some in terms of term loan from the bank for the at least INR 65 to 70 CR of the term loan and remaining from internal funds”
Punit Rasadia, page 7 of the filed PDF · View the filing
Export contribution — around 60% · FY27
stated as an aspiration by Punit Rasadia
p. 11
“we are trying to do the at least somewhere around 60% of the export contribution in this FY27”
Punit Rasadia, page 11 of the filed PDF · View the filing
New APIs launch — seven new APIs · FY27
stated firmly by Punit Rasadia
p. 3
“launching of seven new APIs in FY27 across additional therapeutic categories”
Punit Rasadia, page 3 of the filed PDF · View the filing
DMF filings — three to five additional DMF · FY27
stated firmly by Punit Rasadia
p. 3
“filing three to five additional DMF in FY27 to deepen regulated market penetration and long-term revenue visibility”
Punit Rasadia, page 3 of the filed PDF · View the filing
PAT — INR 45 crore · FY27
stated conditionally by Punit Rasadia
p. 17
“Yeah, we are right now actually on the conservative side, we are expecting the INR 45 CR of the PAT”
Punit Rasadia, page 17 of the filed PDF · View the filing
Receivable days — at least 180 days · end of FY27
stated firmly by Punit Rasadia
p. 13
“by end of this FY27 with the positive cash flow and receivable days will remain at least 180 days, which is I think mostly API manufacturer is having”
Punit Rasadia, page 13 of the filed PDF · View the filing
Inventory reduction — 20 to 25% · Q2 FY27
stated conditionally by Punit Rasadia
p. 14
“I think we'll reduce our inventory whatever right now here in Q2 somewhere around 20 to 25% will be liquidated without any doubt”
Punit Rasadia, page 14 of the filed PDF · View the filing
Fresh credit rating — triple B minus minimum · within next 45 days
stated conditionally by Punit Rasadia
p. 19
“we have been assured that it will be somewhere triple B minus minimum at least”
Punit Rasadia, page 19 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management reiterated confidence and gave a range of INR 380-400 crore for FY27.
Answered by Punit Rasadia
Asked by Disha: What is the FY27 revenue guidance given the 30% CAGR target?
p. 3
“we are still remain the bullish on the revenue numbers what we have given to you”
Punit Rasadia, page 3 of the filed PDF · View the filing
Order book stood at INR 280-300 crore with expectation of additional business to reach the full-year target.
Answered by Punit Rasadia
Asked by Paras Chheda: What is the current order book against the FY27 revenue target?
p. 6
“we are sure that within the year, additional INR 80 to 90 CR business on the basis of the product that we can clear it”
Punit Rasadia, page 6 of the filed PDF · View the filing
Management said no current plan for equity dilution, preferring term loans and internal accruals, with rights issue as a fallback.
Answered by Punit Rasadia
Asked by Paras Chheda: Will the company need equity dilution to fund FY28 growth?
p. 7
“Right now there is no planning, but I think once the capacity will be completed and we'll come with the commercial production, at that time we'll see that whatever the situation and if required, then our first preference is go with the financial institution instead of going further for the dilution or maybe we can go for the rights issue or something instead of private placement”
Punit Rasadia, page 7 of the filed PDF · View the filing
Management attributed the decline to higher operating costs from acquisitions and raw material price increases not yet passed to customers, expecting recovery.
Answered by Punit Rasadia
Asked by Ashish Parikh: What caused the Q4 EBITDA margin decline and will Q1 recover?
p. 9
“I think in Q1 that EBITDA margin will be more or less similar with the previous whole year's EBITDA margin with the numbers of also EBITDA”
Punit Rasadia, page 9 of the filed PDF · View the filing
Management said margins should return near 30% and backward integration in Apiqo would help profitability from Q2.
Answered by Punit Rasadia
Asked by Bhavesh Patel: Are the lower 25-30% EBITDA margins structural or transient, and what backward integration benefits have been realized?
p. 10
“we are on the verge to able to get the higher prices from our customer and we've able to maintain the same EBITDA what we've confirmed between somewhere around 30%”
Punit Rasadia, page 10 of the filed PDF · View the filing
Management said past receivables were delayed but not defaulted, and expects around 180 days going forward.
Answered by Punit Rasadia
Asked by Rudraksh Raheja: Why are receivable days still above 200 days versus the stated market norm?
p. 13
“there was some incident happened due to that some of our receivable was delayed. It is not defaulted as I have mentioned in our previous meeting also to you”
Punit Rasadia, page 13 of the filed PDF · View the filing
Management confirmed partial recovery with the remainder expected within a quarter.
Answered by Punit Rasadia
Asked by Achyut Prabhat: Has the company recovered the pending receivable from the distributor lost in late 2025?
p. 16
“So right now it is somewhere around INR17 CR outstanding”
Punit Rasadia, page 16 of the filed PDF · View the filing
Management said it will use a bank term loan of INR 65-70 crore plus internal accruals, avoiding equity dilution.
Answered by Punit Rasadia
Asked by Purva Shah: How will the INR 130 crore capex be funded given the balance sheet position?
p. 18
“we don't want to go for any equity dilution. Right now we'll go with the bank loan, term loan for the around INR 65 to 70 CR”
Punit Rasadia, page 18 of the filed PDF · View the filing
Management said the CARE rating issue was historical and related to a dispute, and a fresh Brickwork rating is expected soon.
Answered by Punit Rasadia
Asked by Purva Shah: Can you explain the CARE 'issuer not cooperating' credit rating remark?
p. 18
“CARE was doing the literally blackmailing to get the money and doing all that activity and finally we have not given them a single penny for withdrawing that rating, that's why they have published”
Punit Rasadia, page 18 of the filed PDF · View the filing
Risks flagged
Raw material price volatility and disrupted global supply chain affecting EBITDA margin
p. 4
“the prices of raw material and global supply chain is totally disturbed, so I think it is not possible for me to predict what is going to happen after this quarter and what will be the situation”
Punit Rasadia, page 4 of the filed PDF · View the filing
Delayed customer price pass-through impacting EBITDA in the near term
p. 8
“we were holding the purchase order with the previous prices that we have not increased with the customer. So, it directly impact on the EBITDA and EBITDA margin”
Punit Rasadia, page 8 of the filed PDF · View the filing
Daily volatility in solvent and raw material prices creating uncertainty
p. 9
“nowadays prices of most of the common solvents and raw materials with the validity of only one day. If you are not confirmed, then tomorrow will be the next new prices”
Punit Rasadia, page 9 of the filed PDF · View the filing
Delayed customer payments extending receivable cycles
p. 19
“this all habit for making the payment delayed is by the Indian traders and distributor”
Punit Rasadia, page 19 of the filed PDF · View the filing
Increased supplier credit costs due to working capital pressures from price increases
p. 20
“their working capital requirement is also increased due to the prices increase more than 100%”
Punit Rasadia, page 20 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.